- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06106152
WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody
March 24, 2024 updated by: Pingli Wang, Second Affiliated Hospital, School of Medicine, Zhejiang University
A Single-center, Open Label, Exploratory Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of WTX212A Injection Combined With PD -1/PD-L1 Monoclonal Antibody in Patients With Advanced Lung Cancer
This trial is a single-center, open-label designed investigator-initiated clinical study (IIT) to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of WTX212A injection WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with advanced lung cancer
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The trial consist of Screening Period (30 days), Treatment Period (21*n days), Safety Follow-up Period (90 days) and Survival follow-up.
About 20 subjects are planned to be enrolled in the study.
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: pingli wang, phD
- Phone Number: (0571)87783520
- Email: pingliwang@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- Recruiting
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University
-
Contact:
- Pingli Wang, M.D
- Phone Number: +86 135 1680 8409
- Email: pingliwang@zju.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- The subject signs an informed consent form, understands this study, is willing to follow and has the ability to complete all experimental procedures;
- Regardless of gender, aged 18 to 75 years old (including threshold);
- Histologically or cytologically confirmed locally advanced (stage IIB/IIC) or metastatic (stage IV) non-small cell lung cancer (NSCLC) with disease progression or intolerance after treatment or extensive stage small cell Lung cancer (SCLC)
- Patients with lung cancer who have been treated with at least 1 line system therapy or cannot currently receive standard therapy, and who have been treated with PD-1 or PD-L1 inhibitor antibody in the terminal line therapy regimen for ≥ 2 cycles;
- ECOG ≤1
- Expected life ≥ 3 months;
- Male participants, their spouses, and female participants of childbearing age should agree to use a medically recognized effective contraceptive method from the signing of the informed consent form until 3 months after the last administration;
Exclusion Criteria:
- People with other serious medical diseases, including but not limited to: uncontrolled diabetes, active peptic ulcer, active bleeding, etc., and people with uncontrollable or serious cardiovascular diseases,
- Patients with clinical symptoms and the need for repeated drainage of pleural and ascitic fluids;
- Previous or recent history of pulmonary fibrosis, severe lung function damage caused by pneumoconiosis, radiation pneumonia, and drug-related pneumonia;
- There have been adverse events related to the use of IO drugs that require permanent cessation of IO treatment;
- Known to have other malignant tumors, currently progressing or completing treatment at least once in the past 3 years. Exceptions include early tumors that have received radical treatment (carcinoma in situ or grade 1 tumor, non ulcerative primary melanoma with a depth of less than 1mm and no lymph nodes involved), skin basal cell carcinoma, skin squamous cell carcinoma, cervical carcinoma in situ, or breast carcinoma in situ that has received potential radical treatment;
- Subjects with symptomatic central nervous system (CNS) metastasis confirmed by imaging or pathological examination and clinically unstable for at least 14 days prior to enrollment who require steroid treatment;
- Having hereditary bleeding tendencies or coagulation disorders, or a history of thrombosis, hemolysis, or hemorrhagic diseases;
- Received significant surgical treatment or obvious traumatic injury within 28 days prior to the start of research treatment;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fixed-dose in patients with advanced lung cancer
WTX212A injection Fixed-dose in advanced lung cancer patients
|
The WTX212A infusion is given every 21 days
Other Names:
|
Experimental: Combined Study in patients with advanced lung cancer
Fixed-dose WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with advanced lung cancer
|
The WTX212A infusion is given every 21 days
Other Names:
The PD -1/PD-L1 monoclonal antibody is given every 21 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the efficacy of WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in the treatment of patients with IO- resistant advanced lung cancer.
Time Frame: 1 year
|
Overall Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the safety of WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in the treatment of IO- resistant advanced lung cancer patients
Time Frame: 1 year
|
The incidence of adverse events (AE), treatment related adverse events (TRAE), and severe adverse events (SAE) during the treatment of WTX212A injection
|
1 year
|
To evaluate the pharmacokinetic ( PK ) characteristics of WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with IO- resistant advanced lung cancer
Time Frame: 1 year
|
Peak Plasma Concentration (Cmax)
|
1 year
|
To evaluate the immunogenicity of WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with IO -resistant advanced lung cancercheckpoint inhibitor resistance in advanced lung cancer patients
Time Frame: 1 year
|
Describe the percentage of anti-drug antibodies (ADA) produced by subjects at each time point after treatment
|
1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the pharmacodynamics ( PD ) characteristics of WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with IO- resistant advanced lung cancer
Time Frame: 1 year
|
The occupancy rate of PD-1 receptor on the surface of peripheral blood T cells in subjects after WTX212A infusion
|
1 year
|
To explore and evaluate WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in the treatment of IO- resistant advanced lung cancer before and after treatment, analysis of immune cell subpopulations
Time Frame: 1 year
|
Calculate the absolute values and percentages of immune cell subpopulations (absolute values and percentages of effector cells and immunosuppressive cells) before and after treatment of WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in the treatment of IO -resistant advanced lung cancer.
Immunomic analysis Variety
|
1 year
|
To explore and evaluate the changes in spleen size in patients with IO- resistant advanced lung cancer before and after treatment with WTX212A injection combined with PD -1/PD-L1 monoclonal antibody
Time Frame: 1 year
|
Changes in spleen size before and after treatmen
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: pingli wang, phD, Second Affiliated Hospital, School of Medicine, Zhejiang University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 5, 2023
Primary Completion (Estimated)
October 30, 2024
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
October 17, 2023
First Submitted That Met QC Criteria
October 27, 2023
First Posted (Actual)
October 30, 2023
Study Record Updates
Last Update Posted (Actual)
March 26, 2024
Last Update Submitted That Met QC Criteria
March 24, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Antibodies
- Immunoglobulins
- Antibodies, Monoclonal
- Immune Checkpoint Inhibitors
Other Study ID Numbers
- Reboot-105
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
There are no plans to disclose the data
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Lung Cancer
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
Mersana TherapeuticsCompletedAdvanced Breast Cancer | Advanced Gastric Cancer | Advanced Nonsmall Cell Lung CancerUnited States
-
NeogenTCNot yet recruitingAdvanced Breast Cancer | Advanced Lung Cancer
-
Shanghai Fosun Pharmaceutical Industrial Development...RecruitingAdvanced Solid Tumor | Advanced Cancer | Lung Cancer, Nonsmall CellChina
-
Ruijin HospitalRecruitingAdvanced Cancer | Locally Advanced Cancer | Pulmonary NeoplasmChina
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerFrance, Korea, Republic of, United Kingdom, Spain
-
Arcus Biosciences, Inc.RecruitingAdvanced CancerUnited States
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerBelgium, United States, Korea, Republic of, Taiwan, United Kingdom, Netherlands
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerUnited States, France, Germany, Korea, Republic of, Taiwan, United Kingdom, Spain, Italy, Japan, Australia
-
Mirati Therapeutics Inc.TerminatedAdvanced CancerUnited States
Clinical Trials on WTX212A injection
-
Zhejiang UniversityNot yet recruitingUnresectable or Metastatic Advanced Solid Tumors
-
National Taiwan University HospitalRecruitingOsteoarthritis (OA) of the KneeTaiwan
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Enrolling by invitationAdvanced Malignant TumorsChina
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingER Positive/HER2 Low Breast CancerChina
-
Dalia Salah SaifUnknownRA - Rheumatoid ArthritisEgypt
-
United States Naval Medical Center, San DiegoCEL-SCI CorporationTerminated
-
Royan InstituteCompletedMyocardial InfarctionIran, Islamic Republic of